德睿智药科技有限公司
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
MindRank Announces First-in-Human Phase 1 Study of MDR-001 in China 2023-06-14 20:00
MindRank Announces First-in-Human Phase 1 Study of MDR-001 in China 2023-06-14 20:00
MindRank Announces U.S. FDA Clearance of IND Application for MDR-001, a Novel GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes and Obesity 2022-12-26 23:00
MindRank Begins IND-enabling Studies of its first AI-designed Drug, 8 Months After Program Initiation 2022-01-18 17:17
1